Agios Pharmaceuticals, Inc.

AGIO · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$103-$112-$89-$97
Dep. & Amort.$1$1$1$1
Deferred Tax$0$0$0$0
Stock-Based Comp.$12$15$11$11
Change in WC-$0$8-$37-$46
Other Non-Cash$2$11$2-$3
Operating Cash Flow-$88-$77-$111-$133
Investing Activities
PP&E Inv.-$2-$1-$1-$1
Net Acquisitions$0$0$0$0
Inv. Purchases-$175-$131-$175-$198
Inv. Sales/Matur.$272$221$288$150
Other Inv. Act.$0-$10$0$0
Investing Cash Flow$96$79$113-$49
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$4$0$2$5
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$4$0$2$5
Forex Effect$0$0$0$0
Net Chg. in Cash$12$2$3-$177
Supplemental Information
Beg. Cash$81$79$76$254
End Cash$93$81$79$76
Free Cash Flow-$90-$78-$112-$134
Agios Pharmaceuticals, Inc. (AGIO) Financial Statements & Key Stats | AlphaPilot